SCHEMBL2929529

SCHEMBL2929529

Fc1ccc(-c2nc3nn(CCN4CCOCC4)cc3c(-c3ccc(F)cc3)c2-c2ccncc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.52
MAPK13 O15264 6/20 0.52
MAPK12 P53778 6/20 0.52
MAPK11 Q15759 6/20 0.52
ALOX5 P09917 1/20 0.46
MAPT P10636 2/20 0.43
POLB P06746 2/20 0.43
RECQL P46063 1/20 0.43
CSNK1D P48730 2/20 0.41
CSNK1E P49674 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
MAP4K4 O95819 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
MAPK9 P45984 1/20 0.39
PRKD2 Q9BZL6 1/20 0.39
SLK Q9H2G2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386983 0.95 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL1385074 0.92 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL1383992 0.91 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL1384099 0.89 MAPK14 (0.41) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL2926768 0.88 MAPK14 (0.40) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL1385753 0.88 SRC (0.43) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1383826 0.87 MAPK14 (0.39) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL2929523 0.87 MAPK14 (0.39) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL1386431 0.87 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL1386122 0.85 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK13 36/4885MAPK12 38/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.